Condition: Oral Squamous Cell Carcinoma · Sponsor: Hospital of Stomatology, Wuhan University
The purpose of this study is to investigate the survival benefit of neoadjuvant anti-PD-1 immunotherapy plus TP chemotherapy compared with TP chemotherapy or up-front surgery in resectable locally advanced oral squamous cell carcinoma.
This description comes directly from the study's public registry record.
Gang Chen, M.D. · +86 02787686215 · geraldchan@whu.edu.cn
Always discuss trial participation with your own doctor first.
| Peking university Shenzhen hospital | Shenzhen, Guangdong, China | Not Yet Recruiting |
| Hospital of Stomatology, Wuhan University | Wuhan, Hubei, China | Recruiting |
| Xiangya Hospital of Central South University | Changsha, Hunan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05798793